Tailing Pharmaceutical (01011) announced that the board of directors recommended a share consolidation based on the basis of merging issued and unissued shares with a face value of $0.0000,0008 per 10 shares into a consolidated share of $0.0000008 per share.
On the date of this announcement, existing shares were traded on the Stock Exchange with 500 existing shares per lot. After the share merger comes into effect, it is proposed that each trading unit traded on the Stock Exchange be changed from 500 existing shares to 10,000 consolidated shares.